Influence of <i>NUCB</i>/Nesfatin-1 Polymorphism on Treatment Response to Naltrexone/Bupropion SR in Binge Eating Disorder and Obesity
2024
Elvira Anna Carbone | Mariarita Caroleo | Marianna Rania | Renato de Filippis | Francesca Condoleo | Federica Catalano | Matteo Aloi | Pasquale De Fazio | Franco Arturi | Marta Letizia Hribal | Teresa Vanessa Fiorentino | Cristina Segura-Garcia
<i>Background and Objectives</i>: The <i>NUCB2</i> gene and its polymorphisms were identified as novel players in the regulation of food intake, potentially leading to obesity (OBE) and altered eating behaviors. Naltrexone/bupropion SR (NB) showed good efficacy and tolerability for treating OBE and altered eating behaviors associated with binge eating disorder (BED). This prospective study investigates the influence of <i>NUCB2</i> gene polymorphism on NB treatment response in OBE and BED. <i>Materials and Methods</i>: Body mass index (BMI), eating (EDE-Q, BES, NEQ, GQ, Y-FAS 2.0) and general psychopathology (BDI, STAI-S) were evaluated at baseline (t0) and after 16 weeks (t1) of NB treatment in patients with OBE and BED (Group 1; <i>N</i> = 22) vs. patients with OBE without BED (Group 2; <i>N</i> = 20). Differences were evaluated according to the rs757081 <i>NUCB2</i> gene polymorphism. <i>Results</i>: <i>NUCB2</i> polymorphism was equally distributed between groups. Although weight at t0 was higher in Group 1, weight loss was similar at t1 in both groups. BMI was not influenced by <i>NUCB2</i> polymorphism. In Group 1, the CG-genotype reported significant improvement in eating psychopathology while the GG-genotype reported improvement only for FA. No differences were observed in Group 2. <i>Conclusions</i>: Patients diagnosed with BED and treated with NB exhibited a more favorable treatment response within the CG-genotype of the <i>NUCB2</i> polymorphism.
Show more [+] Less [-]AGROVOC Keywords
Bibliographic information
This bibliographic record has been provided by Directory of Open Access Journals